Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition

Area of Science:

• Oncology
• Cell Biology
• Biochemistry

Background:

• Mitochondrial oxidative phosphorylation (OxPhos) is a key metabolic process implicated in melanoma drug resistance.
• Resistance to mitogen-activated protein kinase (MAPK) pathway inhibitors in melanoma is a significant clinical challenge.
• Directly targeting mitochondria therapeutically presents considerable difficulties.

Purpose of the Study:

• To explore novel therapeutic strategies for overcoming MAPK inhibitor resistance in melanoma.
• To investigate the role of mTOR kinase signaling in regulating mitochondrial metabolism in resistant melanoma.
• To elucidate the mechanism by which mTOR inhibition impacts OxPhos and resensitizes melanoma cells.

Main Methods:

• Utilized melanoma cell lines with acquired resistance to MAPK inhibitors.
• Employed pharmacological inhibition of mTOR kinase activity.
• Assessed mitochondrial oxidative phosphorylation (OxPhos) levels via metabolic assays.
• Evaluated melanoma cell response to MAPK inhibitors following mTOR inhibition.

Main Results:

• Inhibition of mTOR kinase activity effectively resensitized MAPK inhibitor-resistant melanoma cells.
• mTOR inhibition led to a significant reduction in mitochondrial oxidative phosphorylation (OxPhos).
• A novel indirect mechanism linking mTOR activity to OxPhos was identified.

Conclusions:

• Targeting mTOR kinase represents a promising therapeutic approach to overcome OxPhos-mediated resistance to MAPK inhibitors in melanoma.
• Indirectly modulating mitochondrial metabolism via mTOR offers a viable strategy when direct mitochondrial targeting is challenging.
• These findings provide a foundation for developing combination therapies for refractory melanoma.